These results suggest that the NRF2 inhibitor ML385 can reduce NRF2 and FATP2 levels, thereby resulting in a reduction in fatty acid absorption and an amelioration of VPA-mediated hepatic steatosis (Figure 8R). Here, SLC27A2 is linked to fatty liver disease.